: The broad objective of these studies is to further understand the processes that regulate cholesterol movement across plasma membranes and across the blood brain barrier of the central nervous system. These studies have direct relevance to two broad areas of clinical medicine: the mechanisms of neurodegeneration and dementia and the formation of atherosclerosis. In general, all of these studies will be undertaken using a variety of knockout mice that lack one or more critical proteins for sterol movement. Absolute rates of cholesterol flux across the plasma membranes of various tissues or across the blood brain barrier will be measured and neurological and hepatic function will be assessed. The first set of experiments will investigate the possible role of apoE, ABCA1, SR-BI and LDLR in the movement of cholesterol between the CMS and the plasma. A second set of experiments will test the hypothesis that cholesterol and ganglioside accumulation leads to neurodegeneration in mice with a mutation in NPC1. A third set of studies will explore various agents that might alter the rate of neuron death in the brain and ameliorate the neurological dysfunction seen in Niemann-Pick type C disease. Mice (and children) with NPC disease also develop serious liver abnormalities. A fourth group of studies will explore new pharmaceutical agents that interrupt the enterohepatic circulation of cholesterol and might prevent such liver cell death. The protein ABCA1 is expressed ubiquitously in every organ, including the central nervous system but its exact function in promoting cholesterol transport is unknown. In a fifth set of studies, absolute cholesterol flux rates will be measured in every organ under conditions where this protein is either deleted or over expressed. A sixth set of studies will examine the relationship between NPC1L1, ACAT-2 and ABCA1 in regulating cholesterol flow through the enterohepatic circulation and, hence, the level of LDL-C. Finally, studies are also planned to explore the molecular regulation of the alternative pathway for bile acid synthesis that is initiated by sterol 27-hydroxylase. With the information gained from these studies, it is possible that new therapies can be developed to prevent neurodegeneration with dementias such as Alzheimer's disease, and to prevent atherosclerosis and diseases such as acute coronary occlusion.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL009610-43
Application #
7225967
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Ershow, Abby
Project Start
1965-06-01
Project End
2010-03-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
43
Fiscal Year
2007
Total Cost
$801,514
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Lopez, Adam M; Chuang, Jen-Chieh; Turley, Stephen D (2018) Impact of loss of SOAT2 function on disease progression in the lysosomal acid lipase-deficient mouse. Steroids 130:7-14
Lopez, Adam M; Chuang, Jen-Chieh; Posey, Kenneth S et al. (2017) Suppression of brain cholesterol synthesis in male Mecp2-deficient mice is age dependent and not accompanied by a concurrent change in the rate of fatty acid synthesis. Brain Res 1654:77-84
Chuang, Jen-Chieh; Lopez, Adam M; Turley, Stephen D (2017) Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe. Biochem Pharmacol 135:116-125
Lopez, Adam M; Chuang, Jen-Chieh; Posey, Kenneth S et al. (2017) 'Corrigenda to ""Suppression of brain cholesterol synthesis in male Mecp2-deficient mice is age dependent and not accompanied by a concurrent change in the rate of fatty acid synthesis"" [Brain Res. 1654 (2017) 77-84]'. Brain Res 1657:383
Lopez, Adam M; Chuang, Jen-Chieh; Posey, Kenneth S et al. (2015) PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice. J Pharmacol Exp Ther 355:159-67
Jones, Ryan D; Lopez, Adam M; Tong, Ernest Y et al. (2015) Impact of physiological levels of chenodeoxycholic acid supplementation on intestinal and hepatic bile acid and cholesterol metabolism in Cyp7a1-deficient mice. Steroids 93:87-95
Ramirez, Charina M; Lopez, Adam M; Turley, Stephen D (2015) Lysosomal Acid Lipase Activity: A Tool for the Detection and Management of Fatty Liver Disease? EBioMedicine 2:638-9
Lopez, Adam M; Terpack, Sandi J; Posey, Kenneth S et al. (2014) Systemic administration of 2-hydroxypropyl-?-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin Exp Pharmacol Physiol 41:780-7
Chuang, Jen-Chieh; Lopez, Adam M; Posey, Kenneth S et al. (2014) Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease. Biochem Biophys Res Commun 443:1073-7
Aqul, Amal; Lopez, Adam M; Posey, Kenneth S et al. (2014) Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice. Am J Physiol Gastrointest Liver Physiol 307:G836-47

Showing the most recent 10 out of 33 publications